Search
RTP-801i
go.drugbank.com/drugs/DB06048InvestigationalRTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...
TB-402
go.drugbank.com/drugs/DB06050InvestigationalTB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
DTS-201
go.drugbank.com/drugs/DB06071ExperimentalDTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
CTS-21166
go.drugbank.com/drugs/DB06073InvestigationalCTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.
PX-478
go.drugbank.com/drugs/DB06082InvestigationalPX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.
Apatorsen
go.drugbank.com/drugs/DB06094InvestigationalApatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers
IMC-1C11
go.drugbank.com/drugs/DB06101ExperimentalIt is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Categories: Serotonin 5-HT2 Receptor Antagonists